Author:
Gardiner Robert A.,Frydenberg Mark
Publisher
Springer Berlin Heidelberg
Reference10 articles.
1. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, REDUCE Study Group (2010) Effect of Dutasteride on the risk of prostate cancer. N Eng J Med 362:1192–1202
2. Andriole GL, Crawford ED, Grubb RL 3rd et al (2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104(2):125–132
3. Katelaris NC, Bolton DM, Weerakoon M et al (2015) Current role of multiparametric magnetic resonance imaging in the management of prostate cancer. Korean J Urol 56(5):337–345
4. Prostate-Specific Antigen (PSA) testing in asymptomatic men (2014)
https://www.nhmrc.gov.au/health-topics/testing-prostate-cancer/prostate-specific-antigen-psa-testing-expert-advisory-group
5. Roobol MJ, Schröder FH, Crawford ED, Freedland SJ, Sartor AO, Fleshner N, Andriole GL (2009) A framework for the identification of men at increased risk for prostate cancer. J Urol 182:2112–2120